We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of p... Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome. Show more
CORAL GABLES, Fla., April 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on...
CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing...
AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in the U.S. by Prescription for...
CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on...
Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an 82.0% Increase Compared to...
CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
CORAL GABLES, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.35 | -8.42170929507 | 16.03 | 16.25 | 14.585 | 2372519 | 15.11966401 | CS |
4 | -1.61 | -9.88336402701 | 16.29 | 16.5 | 14.585 | 1355268 | 15.36848863 | CS |
12 | 0.17 | 1.17160578911 | 14.51 | 17.495 | 13.1161 | 1359608 | 15.3159519 | CS |
26 | 1.93 | 15.137254902 | 12.75 | 17.495 | 11.89 | 1412609 | 14.75821352 | CS |
52 | -1.59 | -9.77258758451 | 16.27 | 17.765 | 11.09 | 1484037 | 13.98397581 | CS |
156 | 10.1 | 220.524017467 | 4.58 | 22.11 | 4.43 | 1616190 | 12.38099848 | CS |
260 | 9.28 | 171.851851852 | 5.4 | 22.11 | 2.235 | 1769625 | 8.67126246 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions